Curium Prices Generic Radioligand at 5% Discount to Novartis' Lutathera

· Health

Curium has set the list price for Bexlutry, its radiosimilar to Novartis' Lutathera, at $63,524 per infusion — about a 5% discount to the cost of the pharma giant's drug, according to Endpoints News. The move challenges Novartis in the tricky field of radiopharmaceuticals. Lutathera is a peptide receptor radionuclide therapy used in certain neuroendocrine tumors. A radiosimilar is a follow-on version of a radiopharmaceutical, analogous to a generic or biosimilar. Curium's pricing strategy signals the arrival of competition in a specialized segment where manufacturing and supply chain complexity have historically limited entrants. The modest discount may aim to gain share without triggering aggressive price erosion, but it establishes a second source for a therapy that has been dominated by a single manufacturer, potentially affecting payer and provider choices.

Why it matters：Radiopharmaceuticals are a high-growth oncology niche where competition has been scarce; a discounted radiosimilar could pressure pricing, expand access and encourage more entrants into a complex manufacturing field.

Key points

  • Curium set Bexlutry's list price at $63,524 per infusion, about 5% below Novartis' Lutathera.
  • Bexlutry is a radiosimilar, a follow-on version of a radiopharmaceutical.
  • The move challenges Novartis in the specialized radiopharmaceutical field.

Sources (original reporting)

More stories from this day